Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio
Corroborated by 5 sources from 5 publishers
TL;DR
Reports differ across sources; according to wsj.com, biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion.
Sources
1
Bloomberg Industries
https://www.bloomberg.com/news/articles/2026-03-31/biogen-to-buy-apellis-for-5-6-billion-to-boost-kidney-franchise
2
Dow Jones U.S. Business
https://www.wsj.com/tech/biotech/biogen-to-acquire-apellis-pharmaceuticals-for-5-6-billion-c3bfda6b?mod=pls_whats_news_us_business_f
3
MarketWatch Top Stories
https://www.marketwatch.com/story/biogen-will-acquire-a-drug-company-for-5-6-billion-to-expand-work-in-kidney-diseases-f9672a8f?mod=mw_rss_topstories
4
CNBC 100003114
https://www.cnbc.com/2026/03/31/biogen-to-buy-apellis-pharmaceuticals.html
5
Yahoo Finance News
https://www.investors.com/news/technology/biogen-apellis-pharmaceuticals-buyout-syfovre-empaveli?src=A00220&yptr=yahoo